U.S. patent application number 11/230808 was filed with the patent office on 2006-05-25 for method and system for treating depressive and anxiety disorders.
This patent application is currently assigned to Medtronic, Inc.. Invention is credited to Keith Robert Hildebrand.
Application Number | 20060111690 11/230808 |
Document ID | / |
Family ID | 32680874 |
Filed Date | 2006-05-25 |
United States Patent
Application |
20060111690 |
Kind Code |
A1 |
Hildebrand; Keith Robert |
May 25, 2006 |
Method and system for treating depressive and anxiety disorders
Abstract
A method and system for treating depressive and anxiety
disorders is disclosed. The method and system of the present
invention comprises operating a programmable pump for the delivery
of at least one therapeutic substance into the cerebrospinal fluid
of a patient for the treatment of depressive or anxiety disorders.
In an embodiment, a sensor implanted in a patient may be used in
combination with the programmable pump and catheter.
Inventors: |
Hildebrand; Keith Robert;
(Houlton, WI) |
Correspondence
Address: |
BANNER & WITCOFF, LTD.
TEN SOUTH WACKER DRIVE
SUITE 3000
CHICAGO
IL
60606
US
|
Assignee: |
Medtronic, Inc.
Minneapolis
MN
|
Family ID: |
32680874 |
Appl. No.: |
11/230808 |
Filed: |
September 20, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10335832 |
Jan 2, 2003 |
|
|
|
11230808 |
Sep 20, 2005 |
|
|
|
Current U.S.
Class: |
604/506 |
Current CPC
Class: |
A61M 5/14276 20130101;
A61M 5/1723 20130101 |
Class at
Publication: |
604/506 |
International
Class: |
A61M 31/00 20060101
A61M031/00 |
Claims
1. A method of using a corticotropin-releasing factor antagonist to
treat a depressive or an anxiety disorder in a patient by means of
a programmable pump and a catheter, the catheter having a proximal
end coupled to the programmable pump and a distal end for infusing
a corticotropin-releasing factor antagonist, the method comprising
the steps of: implanting the catheter so that the distal end of the
catheter is located in cerebrospinal fluid of the patient;
operating the programmable pump to deliver a first rate of the
corticotropin-releasing factor antagonist into the cerebrospinal
fluid of the patient to treat the depressive or the anxiety
disorder; and regulating the programmable pump to deliver a second
rate of the corticotropin-releasing factor antagonist in order to
treat the depressive or the anxiety disorder.
2. The method of claim 1, wherein the step of implanting the
catheter is performed after the depressive or the anxiety disorder
is diagnosed.
3. The method of claim 1, wherein the depressive disorder comprises
bipolar disorder.
4. The method of claim 1, wherein, the corticotropin-releasing
factor antagonist comprises astressin.
5. The method of claim 1, wherein the corticotropin-releasing
factor antagonist comprises D-pheCRF (12-41).
6. The method of claim 1, wherein the corticotropin-releasing
factor antagonist comprises alpha-helicalCRF (9-41).
7. The method of claim 1, wherein the step of regulating the
programmable pump in response to a treatment plan comprises
delivery of a third rate of the corticotropin-releasing factor
antagonist in order to treat the depressive or the anxiety
disorder.
8. The method of claim 1, wherein the anxiety disorder comprises
panic disorder.
9. The method of claim 1, wherein the anxiety disorder comprises
obsessive compulsive disorder.
10. The method of claim 1, wherein the anxiety disorder comprises
generalized anxiety disorder.
11. A method of using a corticotropin-releasing factor antagonist
to treat a depressive or an anxiety disorder in a patient by means
of a programmable pump and a catheter, the catheter having a
proximal end coupled to the programmable pump and a distal end for
infusing a corticotropin-releasing factor antagonist, the method
comprising the steps of: implanting the catheter so that the distal
end of the catheter is located in cerebrospinal fluid of the
patient; implanting a sensor for generating a sensor signal for
detecting the extent of the depressive or the anxiety disorder in
the patient; operating the programmable pump to deliver a first
rate of the corticotropin-releasing factor antagonist into the
cerebrospinal fluid of the patient; and regulating the operation of
the programmable pump in response to the sensor signal to deliver a
second rate of the corticotropin-releasing factor antagonist into
the cerebrospinal fluid of the patient to treat the depressive or
anxiety disorder.
12. The method of claim 11, wherein the depressive disorder
comprises refractory depression.
13. The method of claim 11, wherein the depressive disorder
comprises dysthymia.
14. The method of claim 11, wherein the corticotropin-releasing
factor antagonist comprises astressin.
15. The method of claim 11, wherein the corticotropin-releasing
factor antagonist comprises D-pheCRF (12-41).
16. The method of claim 11, wherein the corticotropin-releasing
factor antagonist comprises alpha-helicalCRF (9-41).
17. A method of using a corticotropin-releasing factor antagonist
to treat a depressive or an anxiety disorder in a patient by means
of an implantable programmable pump and a catheter, the catheter
having a proximal end coupled to the implantable programmable pump
and a distal end for infusing a corticotropin-releasing factor
antagonist, the method comprising the steps of: implanting the
catheter so that the distal end of the catheter is located in
cerebrospinal fluid of the patient; implanting a sensor for
generating a sensor signal for detecting the extent of the
depressive or the anxiety disorder in the patient; operating the
implantable programmable pump to deliver a first rate of the
corticotropin-releasing factor antagonist into the cerebrospinal
fluid of the patient; regulating the operation of the programmable
pump in response to the sensor signal to deliver a second rate of
the corticotropin-releasing factor antagonist into the
cerebrospinal fluid of the patient; and wherein the
corticotropin-releasing factor antagonist is delivered
intrathecally into the patinet's cerebrospinal fluid to treat the
depressive or anxiety disorder..
18. The method of claim 17, wherein the corticotropin-releasing
factor antagonist comprises astressin.
19. The method of claim 17, wherein the corticotropin-releasing
factor antagonist comprises D-pheCRF (12-41).
20. The method of claim 17, wherein the corticotropin-releasing
factor antagonist comprises alpha-helicalCRF (9-41).
Description
[0001] This is a continuation of earlier filed co-pending patent
application Ser. No. 10/335,832, filed Jan. 2, 2003 which is
incorporated herewith by reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention relates to a method and system for treating
depressive and anxiety disorders by means of a programmable pump
and a catheter for the delivery of a therapeutic substance into the
cerebrospinal fluid of a patient.
BACKGROUND OF THE INVENTION
[0003] Depressive disorders are common illnesses that affect more
than 18.8 million Americans. "Depression," National Institute of
Mental Health, Publication No. 00-3561 (2000). Depressive
disorders, as with other illnesses, come in different forms. Three
of the more common depressive disorders include major depression,
dysthymia, and bipolar disorder. Major depression is manifested by
a combination of symptoms that interfere with a person's ability to
function normally, including the ability to work, study, or sleep.
Such disabling episodes of depression may occur only, once but more
commonly occur several times in a person's lifetime. Dysthymia, a
less severe type of depression, involves long term chronic symptoms
that do not disable a person but keep a patient from functioning
well or feeling good. Bipolar disorder is a form of depression that
is characterized by cycling mood changes.
[0004] Significant portions of patients treated for depressive
disorders do not respond to therapies presently available (i.e.,
electroconvulsive therapy (ECT), psychotherapy, and orally
delivered antidepressant medications, or various combinations of
all three therapies). This shortcoming exists despite the
introduction of a variety of new more specific and significantly
safer medications to the market place (e.g., Prozac.RTM.,
Zoloft.RTM., Paxil.RTM.). Approximately 20-30% of patients treated
for depression with antidepressant medications fall into the
category of being treatment-resistant. Janicak, P. G. and Martis,
B. (1998), "Strategies for Treatment-Resistant Depression,"
Clinical Cornerstone 1:58-71; Shelton, R. C. (1999), "Treatment
Options for Refractory Depression," J Clin. Psychiatry 60:57-63;
Joffe, R. T. (1997), "Refractory Depression: Treatment Strategies,
with Particular Reference to the Thyroid Axis," J. Psychiatry
Neurosci. 22:327-331. Moreover, 30% to 50% of patients do not
respond to their initial medication regardless of which class of
drug is chosen. The treatment-resistant population consists of
patients who have been treated unsuccessfully with multiple drug
trials using different classes of orally administered
antidepressants, psychotherapy, and potentially ECT.
[0005] Similar to depressive disorders, anxiety disorders affect
approximately 19 million American adults. "Anxiety Disorders,"
National Institute of Mental Health, Publication No. 00-3879
(2000). Anxiety disorders are serious medical illnesses that
afflict people's lives with overwhelming anxiety and fear. There
are many different anxiety disorders that include panic disorder,
obsessive-compulsive disorder, social phobia, and generalized
anxiety disorder. Though each of these forms of anxiety disorders
may have its own distinct features, they all involve an excessive,
irrational fear and/or dread.
[0006] Similar to results for the treatment of depressive
disorders, a significant portion of patients treated for anxiety
disorders do not respond to therapies presently available (i.e.,
electroconvulsive therapy (ECT), psychotherapy, and orally
delivered antidepressant medications, or various combinations of
all three). This shortcoming exists despite the introduction of a
variety of new more specific and significantly safer medications to
the market place.
ECT
[0007] A method of treatment for patients who have failed to
respond to several classes of therapeutics is ECT. Unfortunately,
ECT also has a failure rate of approximately 30-40%. Walter, G.,
Rey, J. M., and Mitchell, P. B. (1999), "Practitioner Review:
Electroconvulsive Therapy in Adolescents," J Child Psychiatr
40:325-334. ECT is a therapy that has been steadily increasing in
use despite the stigma associated with its historical misuse in
psychiatric medicine. ECT is now generally accepted by the American
Psychiatric Association and the National Institute of Mental Health
as being a safe and effective therapy for major depression. The
side effects associated with ECT are generally mild and include
headache, myalgia, nausea, memory problems, and confusion. Walter,
G., Rey, J. M., and Mitchell, P. B. (1999), "Practitioner Review:
Electroconvulsive Therapy in Adolescents," J Child Psychiatr
40:325-334. Unfortunately, a small percentage of the ECT-treated
patients experience significant cognitive impairments (pre- and/or
post treatment memory deficits of durations of weeks to months),
manic switching, and tachycardia such that treatment most be
discontinued. In addition, ECT requires general anesthesia and a
typical course of 8-12 treatments (each treatment takes
approximately 15 minutes) administered bi- or tri-weekly. Perhaps
the most discouraging aspect of ECT is that greater than half of
the successfully treated ECT patients will relapse into clinical
depression in less than a year. Sackeim, H. A., Prudic, J.,
Devanand, D. P., Decina, P., and Malitz, S. (1990), "The Impact of
Medication Resistance and Continuation Pharmacotherapy on Relapse
Following Response to Electroconvulsive Therapy in Major
Depression," J Clin Psychopharmacol 10:96-104.
Psychotherapy
[0008] Psychotherapy involves talking with a trained mental health
professional, such as a psychiatrist. These therapies help a
patient gain insight into and resolve their problems through verbal
exchange with their psychiatrist. One of the short-term therapies
effective in treating both depressive disorders and anxiety
disorders is the cognitive-behavioral therapy. Treatments tend to
be more successful for mild and moderate forms of depressive and
anxiety disorders and usually require medication or ECT treatment
along with, or preceding, psychotherapy for the best outcome.
Psychoactive Drugs
[0009] The same drugs most commonly used to manage depressive
disorders are used to treat anxiety disorders. There are several
types of antidepressant medications used to treat depressive and
anxiety disorders. Most of the oral antidepressive medications used
today are designed to increase the levels of specific monoamine
neurotransmitters in the brain (e.g., norepinephrine, serotonin,
and dopamine). More recent pharmacologic strategies have focused on
antagonizing the effects of specific peptidergic neurotransmitters
in the brain, namely corticotropin-releasing hormone and substance
P.
Thyrotropin Releasing Hormone
[0010] Thyrotropin-releasing hormone (TRH) is a hypothalamic
tripeptide hormone which stimulates the pituitary gland to secrete
thyroid-stimulating hormone. In addition, TRH functions as a
neurotransmitter and neuromodulator in many areas of the central
nervous system. TRH (also called protirelin) is a drug that has
been studied in the past for the treatment of depression but was
shown to produce unpredictable responses when administered
parenterally (IV or SQ). Itil, T. M., Patterson, C. D., Polvan, N.,
Bigelow, A. and Bergey, B. (1975), "Clinical and CNS Effects of
Oral and IV Thyrotropin-Releasing Hormone in Depressed Patients,"
Dis Nerv Sys 2:529-536; Prange, A. J., Wilson, I. C., Lara, P. D.,
Alitop, L. B. and Breese, G. R. (1972), "Effects of
Thyrotropin-Releasing Hormone in Depression," Lancet 2:999-1002.
Because TRH is a tripeptide that is subject to proteolysis in the
upper gastrointestinal tract, it cannot be administered orally.
[0011] TRH has been administered directly to the CNS for the
treatment of a psychiatric disease. Callahan, A. M., Frye, M. A.,
Marangell, L. B., George, M. S., Ketter, T. A., L'Herrou, T. A. and
Post, R. M., (1997), "Comparative Antidepressant Effects of
Intravenous and Intrathecal Thyrotropin-Releasing Hormone:
Confounding Effects of Tolerance and Implications for
Therapeutics," Biol. Psychiatry 41:264-272; Marangell, L. B.,
George, M. S., Callahan, A. M., Ketter, T. A., Pazzaglia, P. J.,
L'Herrou, T. A., Leverich, G. S. and Post, R. M., (1997), "Effects
of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in
Refractory Depressed Patients," Arch. Gen. Psychiatry 54:214-222.
This treatment, a single intrathecal bolus of TRH, was successfully
used to treat refractory depression in 7 out of 10 patients. With
the exception of sleep deprivation, this is the only therapy that
has been demonstrated to produce a rapid (<24 hr) and dramatic
improvement in the symptoms of severe depression. However, the
study did not involve varying the dosage of the therapeutic
substance.
Serotonin Agonists
[0012] In the case of serotonergic agonists, direct CNS delivery
would be of benefit because many of them only poorly penetrate the
blood-brain barrier.
[0013] A serotonin agonist, sumatriptan, although not used to treat
depression has been used in research studies related to depression
and other psychiatric diseases. Stern et al., describes the chronic
use of parenteral sumatriptan to treat patients with refractory
obsessive-compulsive disorder (OCD). Stern, L., Zohar, J., Cohen,
R., and Sasson, Y., (1998), "Treatment of Severe, Drug Resistant
Obsessive Compulsive Disorder with the 5HT.sub.ID agonist
Sumatriptan," Eur Neuropsychopharmacol 8:325-328. Although these
patients experienced only modest reductions in their OCD behaviors,
they demonstrated significant improvements in their symptoms of
depression as measured by the Hamilton scale. Because sumatriptan
does not readily penetrate the blood-brain barrier, intrathecal
delivery would be expected to significantly increase the efficacy
of this agent. Saxena, P. R., (1992), "Migraine Therapy and 5-HT
Receptor Activity," J Neurol 238:S36-S37. Arranz et al, reported on
reduced 5HT.sub.1D receptor density and binding affinity in brain
tissues of suicide victims. Arranz, B., Erikson, A., Mellerup, E.,
Plenge, P. and Marcusson, J., (1994), "Brain 5HT.sub.1A, 5HT.sub.1D
and 5HT.sub.2 Receptors in Suicide Victims," Biol Psychiatry
35:457-463.
[0014] Although serotonin (5-HT) is not available as a
pharmaceutical agent, certain receptor subtype selective agonists
are (e.g., sumatriptan, ImitrexE manufactured by Glaxo Wellcome,
5-HT.sub.1 receptor selective agonist currently formulated for
injection, 12 mg/ml in saline with no preservatives, indicated use:
migraines). The 5-HT.sub.1A-receptor has been implicated as a major
receptor involved in the antidepressive response to SSRIs. Deakin,
J. F. W., (1998), "5HT.sub.1A Receptors, Depression, and Anxiety,"
Pharmacol Biochem Behav 29:819-830.
[0015] Buspirone, an anxiolytic drug, produces at least part of its
effect by activation of 5-HT.sub.1A receptors. Sussman, N., (1994),
"The Potential Benefits of Serotonin Receptor-Specific Agents," J
Clin Psychiatry 55:45-51. Mirtazapine, a newly FDA-approved
antidepressant (AD), blocks two types of serotonin receptors
(5-HT.sub.2 and 5-HT.sub.3,). Feighner, J. P., (1999), "Mechanism
of Action of Antidepressant Medications," J Clin Psychiatry
60:4-13. Trazodone is another antidepressant that acts to inhibit
neuronal reuptake of serotonin and also antagonizes 5-HT.sub.2
receptors. Ruoff, G. E., (1996), "Depression in the Patient with
Chronic Pain," J Fam Pract 43:S25-S34.
[0016] Nefazodone, a newer AD, inhibits both 5-HT.sub.2 and
5-HT.sub.3 receptors. These antidepressive mechanisms suggest that
activation of 5-HT.sub.2 and 5-HT.sub.3 receptors are not involved
in the same biochemical pathways associated with selective
serotonin reuptake inhibitor (SSRI)-induced efficacy and lends
further support to the intrathecal use of sumatriptan (i.e.,
serotonin-like efficacy without the side effects). The
antidepressive effects of SSRIs appears to involve 5-HT.sub.1
receptors (1A, 1B, and 1D); insomnia and sexual dysfunction effects
have been attributed to 5-HT.sub.2 receptor activation and GI side
effects have been attributed to 5-HT.sub.3 receptor activation.
Thase, M. E., Frazer, A., Gorman, J. M., Hirschfeld, R. M. and
Roose, S. P., (2000), "Pharmacotherapy of Depression: New
Strategies," A Symposium of the American Psychiatric Association
2000 Annual Meeting.
Adrenergic Agonists
[0017] The majority of antidepressants presently used are designed
to affect two major neurotransmitter systems of the brain,
norepinephrine and serotonin. Antidepressants inhibit the neuronal
reuptake (tricyclic antidepressants--norepinephrine (NE) and 5-HT,
SSRIs--just 5-HT, selective norepinephrine reuptake
inhibitors--just NE) or degradation (monoamine oxidase inhibitors)
of one or both of these neurotransmitters. Although this is the
common "first step" pharmacologic effect of antidepressants that
leads to a corresponding increase in synaptic neurotransmitter
concentrations, the precise biochemical pathways which lead to the
ultimate therapeutic outcome have yet to be elucidated. It also is
not appreciated why this pharmacologic first step occurs almost
immediately after the medication is taken, whereas the patient does
not experience relief from his/her symptoms of depression for weeks
afterwards.
[0018] Intrathecal administration of NE has been studied in animal
models of analgesia, spinal cord injury, and motor reflexes. Howe,
J. and Yaksh, T. L., (1982), "Changes in Sensitivity to Intrathecal
Norepinephrine and Serotonin after 6-Hydroxydopamine,
5,6-Dihydroxytryptamine or Repeated Monoamine Administration," J
Pharmacol Exp Ther 220:311-321; Milne, B., Cervenko, F., Jhamandas,
K., Loomis, C. and Sutak, M., (1985), "Analgesic and Tolerance to
Intrathecal Morphine and Norepinephrine Infusion via Implanted
Mini-Osmotic Pumps in the Rat," Pain 22:165-172; Minor, B. G.,
Persson, M. L., Post, C., Jonsson, G. and Archer, T. (1988),
"Intrathecal Noradrenaline Restores 5-Methoxy-N,N-demthyltryptamine
Induced Antinociception Abolished by Intrathecal
6-Hydroxydopamine," J Neural Transm 72:107-120; Brustein, E. and
Rossignol, S. (1999), "Recovery of Locomotion After Ventral and
Ventrolateral Spinal Lesions in the Cat: Effects of Noradrenergic
and Serotoninergic Drugs," J Neurophysiol 81:1513-1530;
Wiesenfield-Hallin, Z., (1987), "Intrathecal Noradrenaline has a
Dose-Dependent Inhibitory or Facilitory Effect on the Flexion
Reflex in the Rat," Acta Physiol Scand 130:507-511. In these
studies, no undesirable or unpredicted responses were attributed to
intrathecal NE administration.
[0019] Recent theories proposed on the biochemical mechanisms of
ADs focus on adrenoceptors and the enzyme responsible for NE
synthesis, tyrosine hydroxylase. Leonard, B. E., (1997),
"Noradrenaline in Basic Models of Depression," Eur
Neuropsychopharmacol 7:511-516. Many ADs produce a decrease in
function and/or adrenoceptor density as well as decreases in the
tyrosine hydroxylase levels in the brain. Thase, M. E., Frazer, A.,
Gorman, J. M., Hirschfeld, R. M. and Roose, S. P., (2000),
"Pharmacotherapy of Depression: New Strategies," A Symposium of the
American Psychiatric Association 2000 Annual Meeting. These are
biochemical endpoints which may be accomplished more effectively by
direct NE infusion.
[0020] The direct infusion of NE as opposed to relying on oral ADs
to inhibit neuronal NE uptake may provide several advantages. Both
methods result in increasing the amount of extracellular NE, but
traditional ADs are limited by the endogenous pool of NE available
in the vesicles of the nerve terminals. By providing an exogenous
source of the transmitter, the concentration of NE may be increased
above the endogenous limit. Those skilled in the art will realize
that in pharmacology drugs that exert their effects indirectly
(i.e., are dependent on the causing the release of or inhibiting
the degradation of a primary endogenous molecule) are usually
limited in the maximum effect they can produce. This efficacy
limitation is a direct result of the limited pool of endogenous
agonist. It is also conceivable that the lack of an adequate
clinical response to oral reuptake inhibitors in select patient
populations is a result of depleted or inaccessible pools of NE
within the terminals of the presynaptic neurons. It is reasonable
to assume that only with an intact endogenous supply of presynaptic
NE can the initial pharmacologic impact of reuptake inhibition be
expected to occur. An exogenous supply of NE would be able to
circumvent this "theoretical" problem. Using exogenous NE may
potentially speed recovery and provide efficacy in patients who
have previously been shown to be resistant to oral therapy.
Corticotropin-Releasing Factor Antagonists
[0021] Corticotropin-releasing factor (CRF) is an endogenous
41-amino-acid peptide that is produced in the brain and which is
critical for mediating responses to stress. It is released by the
hypothalamus and serves to activate the pituitary and adrenal
glands resulting in the release of epinephrine and cortisol into
the blood. It is know in the art of psychiatry that patients with
depression have elevated plasma cortisol levels as a result of an
overactive hypthalamic-pituitary-adrenal (HPA) axis. It is also
appreciated that stress, especially prolonged stress and
early-childhood stress, can induce depression. Since CRF is the
initial chemical mediator of the stress response, drugs which block
the effect of CRF may block this stress cascade and be useful in
treating depression and anxiety disorders. Published scientific
literature supports this but a successful therapeutic that works by
blocking this pathway has yet to make into the clinic.
[0022] Companies are pursuing agents which can be administered
orally similar to all the other drugs which are currently marketed
for depression. A general type of CRF antagonist that can block the
relevant receptors but that cannot be given orally or cross the
blood-brain barrier are peptide antagonists. Although peptide
antagonists are often used in research and function quite
effectively to block the targeted receptor, because they would be
digested in the gastrointestinal tract if given orally and not
cross the blood-brain barrier to reach their site of action if
given IV or SQ, these peptidergic agents have not been pursued as
viable therapeutic candidates.
Substance Pantagonists
[0023] Substance P is an 11-amino-acid endogenous peptide
neurotransmitter that is known to be involved in the transmission
of pain information to the central nervous system. Substance P
produces its effects by activating cell-surface receptors known as
neurokinin-1 (NK-1) receptors. Recently, it has been appreciated
both in animal studies and clinical trials that substance P places
an important role in mediating stress responses and that antagonism
of the NK-1 receptors may have positive effects in treating mood
and anxiety disorders. Kramer, M. S., (1998), "Distinct Mechanism
for Antidepressant Activity by Blockade of Central Substance P
Receptors," Science Volume 281 Sep. 11, 1640-1625. Substance P
concentrations are especially high in the brain structure known as
the amygdala, an important area that regulates mood and
anxiety.
SUMMARY OF THE INVENTION
[0024] One or more of the above-mentioned deficiencies in the art
are satisfied by the method and system of the present invention of
operating a programmable pump for the delivery of at least one
therapeutic substance into the cerebrospinal fluid (CSF) of a
patient for the treatment of depressive or anxiety disorders. The
invention involves the use of at least one therapeutic substance to
treat a depressive or an anxiety disorder in a patient. For
example, a catheter is implanted in a patient, the catheter having
a proximal end coupled to a programmable pump and a distal end for
infusing the at least one therapeutic substance. The distal end of
the catheter is located at or in the cerebrospinal fluid of a
patient. The programmable pump is operated to deliver a first rate
of the at least one therapeutic substance into the cerebrospinal
fluid of the patient to treat the depressive or anxiety disorder.
The programmable pump is regulated in response to a treatment plan
to deliver a second rate of the at least one therapeutic substance
in order to treat the depressive or anxiety disorder.
[0025] In addition, a sensor implanted in a patient may be used in
combination with a programmable pump and a catheter to deliver at
least one therapeutic substance to treat a depressive or an anxiety
disorder in the patient. The sensor is implanted in the patient for
generating a sensor signal detecting the extent of the depressive
or anxiety disorder in the patient. The programmable pump is
operated to deliver a first rate of the at least one therapeutic
substance into the cerebrospinal fluid of the patient. The
programmable pump is regulated in response to the sensor signal to
deliver a second rate of the at least one therapeutic substance to
treat the depressive or anxiety disorder.
[0026] Thus, the programmable pump can adjust the second rate of
the at least one therapeutic substance to optimize treatment. The
sensor can provide signals on a periodic or continuous basis so
that the programmable pump can adjust the delivery of the at least
one therapeutic substance to the patient. Additionally, the use of
a programmable pump as disclosed in this invention allows complex
dosage schemes as opposed to individual bolus doses to avoid the
potential effects of tolerance and accommodate the changing
clinical status of patients.
[0027] These and other advantages and features of the invention
will become apparent upon reading and following the detailed
description and referring to the accompanying drawings which like
numbers refer to like parts throughout.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] FIG. 1 is a diagrammatic illustration of the flow of
cerebrospinal fluid in the subarachnoid space of a patient;
[0029] FIG. 2 is a diagrammatic illustration of a programmable pump
and a catheter implanted in a patient according to the present
invention;
[0030] FIG. 3 is a diagrammatic illustration of a catheter
implanted in a patient's subarachnoid space for the delivery of a
therapeutic substance into the cerebrospinal fluid;
[0031] FIG. 4 is a diagrammatic illustration of a catheter and a
sensor implanted in a patient's brain, the catheter and sensor
attached to a pump for the delivery of a therapeutic substance in
accordance with another embodiment of the invention;
[0032] FIG. 5 is a schematic diagram of a sensor and a converter in
accordance with the present invention;
[0033] FIG. 6 is a flow chart describing closed loop feedback in
accordance with the present invention; and
[0034] FIG. 7 is diagrammatic illustration of a control unit in
accordance with the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] As illustrated in FIG. 1, the central nervous system (brain
and spinal cord) is surrounded by cerebrospinal fluid 6 contained
within the subarachnoid space 3. In addition, cerebrospinal fluid 6
is also contained in the four ventricles of the brain: two lateral
ventricles 1, the third ventricle 2, and the fourth ventricle 5.
The lateral ventricles 1 are connected to the third ventricle 2 via
the foramen of Monro 4; the third ventricle 2 is connected to the
fourth ventricle 5 via the aqueduct of Sylvius 8. The arrows within
the subarachnoid space 3 in FIG. 1 indicate cerebrospinal fluid 6
flow.
[0036] The subarachnoid space 3 is a compartment within the central
nervous system that contains cerebrospinal fluid 6. The
cerebrospinal fluid 6 is produced in the ventricular system of the
brain and communicates freely with the subarachnoid space 3 via the
foramina of Magendie and Luschka.
[0037] Given the limited efficacy of other conventional treatments,
as discussed in the background section, intrathecal delivery of
therapeutics with the use of a programmable pump into the
cerebrospinal fluid 6 offers the potential to treat a large portion
of severely affected patients with depressive and anxiety disorders
who currently have limited options. Depressive disorders that may
be treated by intrathecal delivery of therapeutic substances
through the use of a programmable pump in accordance with the
present invention comprise refractory depression, dysthymia, or
bipolar disorder. Similarly, anxiety disorders that may be treated
by intrathecal delivery of therapeutic substances through the use
of a programmable pump in accordance with the present invention
comprise panic disorder, obsessive-compulsive disorder, generalized
anxiety disorder, or social phobia.
[0038] Intrathecal delivery of therapeutics into the cerebrospinal
fluid is less invasive than intraparenchymal (direct tissue)
delivery of therapeutics. In addition, intrathecal delivery of
therapeutics may not require the need for a neurosurgeon as the
delivery of the therapeutics does not require delivery to a direct
brain target. Numerous other physicians may be qualified to insert
a catheter into the lumbar subarachnoid space of the spinal column
in order to initiate intrathecal therapeutic delivery.
[0039] FIG. 2 illustrates a programmable pump 40 and a catheter 38
in accordance with the present invention. The programmable pump 40
and catheter 38 may be implanted in a patient after diagnosis of a
depressive or anxiety disorder. The programmable pump 40 may take
the form of a Synchromed.RTM. infusion pump as manufactured by
Medtronic, Inc. of Minneapolis, Minn. A reservoir 27 that contains
the therapeutic substance to be delivered is housed in programmable
pump 40. The location of programmable pump 40 implantation is one
in which the implantation interferes as little as practicable with
patient activity, such as subcutaneous in the lower abdomen. The
proximal end 35 of catheter 38 is connected to programmable pump
40. Catheter 38 is a flexible tube with a lumen typically running
the length of catheter 38. The distal end 33 of catheter 38 is
positioned to infuse a therapeutic substance or substances into the
target area of CSF of the patient. The target area of CSF of the
patient may be the subarachnoid space 3 between the fourth cervical
vertebrae (C4) 52 and seventh cervical vertebrae (C7) 54, as shown
in FIG. 3. The programmable pump 40 is operated to discharge a
predetermined dosage of therapeutic or therapeutics into the CSF of
the patient.
[0040] The programmable pump 40 is operatively coupled to and
responsive to electrical signals delivered to it from a control
unit 42. Electrical signals from the control unit 42 could for
example, start and stop the programmable pump 40. As shown in FIG.
7, control circuitry within the control unit 42 would typically
include a microprocessor 72 or similar device, and memory 74. In
addition, control unit 42 contains the appropriate interface
circuitry well known to those skilled in the art to couple
microprocessor 72 to the programmable pump 40. Microprocessor 72
controls the amount of therapeutic substance administered to the
patient according to therapy program instructions stored in memory
74. Memory 74 has the ability to store and retrieve the therapy
program and data.
[0041] The programming of the programmable pump 40 may be
accomplished with an external programmer/control unit via
telemetry. The controlled amount of therapeutic or therapeutics may
be delivered over a specified time period. With the use of the
programmable pump 40, different dosage regimens may be programmed
for a particular patient. Additionally, different therapeutic
dosages can be programmed for different combination of
therapeutics. The programmable pump 40 gives the clinicians the
ability to program different rates of therapeutic delivery that may
be required during the course of a day or during the course of a
treatment regiment. For example, a first rate of at least one
therapeutic substance is delivered into the CSF of patient
according to predefined therapy plan to treat a depressive or an
anxiety disorder. The first rate of therapeutic substance delivered
may correspond to a certain time of day in which a patient is
usually more active, daytime. Next, in accordance with the
predefined therapy plan, a second rate of at least one therapeutic
substance may be delivered corresponding to a different time of day
in which a patient is less active, nighttime. As one skilled in the
art will realize, programmable pump 40 allows for the delivery of
complex therapeutic delivery schemes as opposed to fixed rate
therapeutic delivery. These complex delivery schemes that may
contain a number of different and changing therapeutic delivery
rates such as a first, second, and third rate of delivery.
[0042] The therapeutic substance delivered by programmable pump 40
to treat the depressive or an anxiety disorder may comprise a
serotonin agonist. The serotonin agonist may comprise a 5-HT.sub.1
agonist. The 5-HT.sub.1 agonist may comprise sumatriptan or
buspirone. Alternatively, the therapeutic substance delivered by
programmable pump 40 to treat the depressive or an anxiety disorder
may comprise an adrenergic agonist. The adrenergic agonist may
comprise norepinephrine, epinephrine, and/or isoproterenol.
[0043] Programmable pump 40 may also deliver a
corticotropin-releasing factor antagonist to treat the depressive
or an anxiety disorder. The corticotropin-releasing factor
antagonist may comprise astressin, D-pheCRF (12-41), and/or
alpha-helicalCRF (9-41).
[0044] Additionally, programmable pump 40 may deliver a therapeutic
substance such as a substance P antagonist to treat the depressive
or an anxiety disorder. The substance P antagonist may comprise a
peptide antagonist such as a neurokinin 1 antagonist.
[0045] Also, programmable pump 40 may deliver a
thyrotropin-releasing hormone receptor agonist (TRH-RA) to treat
the depressive or anxiety disorder. The TRH-RA may be selected from
the group consisting of TRH, MK771, (NS-3) CG3703, TA0910, YM14673,
RX77368, RX74355, 2,4-diodo(Im)-TRH, 4(5)-NO.sub.2(Im)-TRH, CG3509,
CG3703, TRH-Gly and PS4.
[0046] The therapeutic substance may also be delivered into the CSF
through a ventricle of the brain. Delivery of a therapeutic
substance through a ventricle of the brain may be advantageous
especially as the structures of the brain, especially the
structures of the limbic system including the amygdala, the locus
coeruleus, and the hypothalamus are the ultimate therapeutic
targets.
[0047] Referring to FIG. 4, catheter 38 is positioned to deliver a
therapeutic substance to a specific infusion site in the brain. The
distal end of catheter 38 terminates in a cylindrical hollow tube
22 having a distal end 115. The distal end 115 of catheter 38 may
be implanted in a ventricle of the brain to provide the therapeutic
substance into a patient's CSF. The proximal end 35 of catheter 38
is coupled to the programmable pump 40.
[0048] A sensor 130 is implanted into a portion of a patient's
central nervous system. As shown in FIG. 4, sensor 130 may comprise
a sensing lead 26 having two sensing electrodes 28 and 30 located
in the patient's brain to measure the electrical activity of a
patient's hypothalamus. Sensor 130 may be placed in the third
ventricle of a patient's brain to measure the electrical activity
of the hypothalamus.
[0049] Another form of sensor 130 may be a chemical sensor that is
capable of detecting the amount of depression-associated analyte
quantified in the CSF or plasma. As one skilled in the art will
realize, one of the most reproducible finding in all of psychiatric
research is the increase in the hypothalamo-pituitary-adrenal axis
activity in depression. Keller, M. B., Schatzberg, A. F., Chamey,
D. S., Krishnan, K. R., Weissman, M. M. and Nemeroff, C. B. (2000),
"Novel Treatments of Depression," A symposium held at the 2000
Annual Meeting of the APA. Accordingly, the level of
corticotropin-releasing hormone in the CSF, or cortisol or
epinephrine in the plasma, may be detected in order to regulate the
amount of therapeutic substance dispensed from the programmable
pump.
[0050] Sensor 130 may be used with a control loop feedback system
in order to automatically determine the amount of therapeutic
substance delivery necessary to treat the depressive or anxiety
disorder. Referring to FIG. 5, the output of sensor 130 may be
connected to a cable 132 comprising conductors 134 and 135.
Conductors 134 and 135 may be connected to the input of an
analog-to-digital converter 140. The output of the
analog-to-digital converter 140 may be connected to control unit
42. Electrical signals from the control unit 42 could, for example,
regulate the rate of therapeutic substance delivery.
[0051] FIG. 6 illustrates a therapeutic program for use with the
present invention. In step 648, a sensor signal 649 is received by
analog-to-digital converter 140. In step 650, the sensor signal 649
is converted from an analog to a digital signal in
analog-to-digital converter 140. The digital signals from the
analog-to-digital converter 140 are read by control unit 42. The
value of the analog-to-digital output 670 may be stored in memory
74 as shown in step 652. Next, control unit 42 determines the
proper therapeutic delivery rate in step 654. The delivery rate
determined in step 654 may be in accordance with predefined limits
programmed into programmable pump 40 by a clinician at the onset of
the therapeutic substance delivery. Control unit 42 then regulates
pump 40 so that pump 40 delivers the therapeutic rate determined by
step 654. Finally, another sensor signal 649 is generated by sensor
130 and the process begins again at step 648.
[0052] The embodiments of the invention, and the invention itself,
are now described in such full, clear, concise and exact terms to
enable a person of ordinary skill in the art to make and use the
invention. To particularly point out and distinctly claim the
subject matters regarded as invention, the following claims
conclude this specification. To the extent variations from the
preferred embodiments fall within the limits of the claims, they
are considered to be part of the invention, and claimed.
* * * * *